Quick Answer
Aspire Biopharma Holdings, Inc. reported Net Income of -$24.48 million for fiscal year 2025.
Aspire Biopharma Holdings, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$24.48M | -1768.9% |
| 2024 | -$1.31M | -129.3% |
| 2023 | $4.46M | +33.6% |
| 2022 | $3.34M | +13211.8% |
| 2021 | -$25.5K | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$1.85M | -755.6% | +6.6% |
| June 30, 2025 | -$1.98M | -1944.2% | +87.6% |
| March 31, 2025 | -$15.94M | -6801.9% | -1981.9% |
| December 31, 2024 | -$765.7K | — | -254.1% |
| September 30, 2024 | -$216.3K | -212.3% | -123.1% |
| June 30, 2024 | -$96.9K | -105.3% | +58.0% |
| March 31, 2024 | -$231.0K | -108.0% | -233.5% |
| September 30, 2023 | -$69.3K | -106.4% | -103.8% |
- Aspire Biopharma Holdings, Inc. showed a decrease of -1768.9% in Net Income compared to the prior fiscal year.
- Over the 2021–2025 period, Aspire Biopharma Holdings, Inc.’s net income has declined by 95997.5% (from -$25.5 thousand to -$24.48 million).
- The most recent figure is from Aspire Biopharma Holdings, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: